Pros

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Monday, April 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

YPrime Survey Reveals Challenges and Opportunities for Streamlining Oncology Trials with eCOA

Retrieved on: 
Wednesday, April 3, 2024
Risk, American Opportunity Tax Credit, Pros, Patient, Uncertainty, Burden, Pressure, Data collection, Clinical trial, Medical imaging

The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA , sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.

Key Points: 
  • The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA , sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.
  • While all clinical trials share similarities, oncology trials present distinct complexities.
  • "By improving patient engagement, streamlining data collection, and enabling real-time insights, eCOA platforms can significantly reduce risk and uncertainty in oncology trials.
  • For a complete analysis of the survey findings and a deeper dive into how eCOA can optimize your oncology trials, download the complimentary report, Decreasing the Burden of Oncology Clinical Trials with eCOA .

Canada Plastics Pact Surpasses 100 Partners, Welcomes Six New Partners To Tackle Plastic Waste and Pollution

Retrieved on: 
Tuesday, April 2, 2024
Partner, EPR, Pros, Environment, Recycling, Interchange, Extended producer responsibility, Polymer, Education, Research, Policy, Food, Private sector, Wind, CPP, Personal protective equipment, Plastic, Collection, Movement, PPE

Denovia Labs is a research company working to reshape plastic waste management.

Key Points: 
  • Denovia Labs is a research company working to reshape plastic waste management.
  • They have developed a proprietary innovative approach to transform various forms of plastic waste back to its base chemical building blocks.
  • Ocean Legacy Foundation is a Canadian-based non-profit organization that develops and implements worldwide plastic pollution response programs, with the goal to end plastic pollution.
  • This guidance was developed by a cross-section of CPP Partners to be used by all Canadian stakeholders that put plastics in the market.

Universal Transit ‘Pros to Know’ Top Supply & Demand Chain Executive 2024 Awards

Retrieved on: 
Tuesday, March 12, 2024
Motivation, Growth, Risk management, Woman, Transport, Pros, Food, Demand

They've spent the last year (and more) creating safer, more efficient supply chains," says Marina Mayer, editor-in-chief of Food Logistics and Supply & Demand Chain Executive.

Key Points: 
  • They've spent the last year (and more) creating safer, more efficient supply chains," says Marina Mayer, editor-in-chief of Food Logistics and Supply & Demand Chain Executive.
  • George Milorava, CEO of Universal Transit, commented on the award, saying: "I am deeply honored to receive the Pros to Know award from Supply & Demand Chain Executive.
  • Supply & Demand Chain Executive is the only supply chain publication covering the entire global supply chain, focusing on trucking, warehousing, packaging, procurement, risk management, professional development and more.
  • Supply & Demand Chain Executive and its sister publication, Food Logistics, also operate SCN Summit and the Women in Supply Chain Forum.

Overhaul's Q1 Triumphs: Leading the Way in Supply Chain Excellence

Retrieved on: 
Monday, April 1, 2024
Transport, Internet of things, Business, Risk, Internet, Pros, Enterprise, Insurance, Supply, Safety, Magic Quadrant, Challenger, Demand, Maintenance (technical)

These accolades highlight the company's continued excellence and innovative contributions to the global supply chain and logistics industry.

Key Points: 
  • These accolades highlight the company's continued excellence and innovative contributions to the global supply chain and logistics industry.
  • We're not just celebrating these achievements; we're motivated by them to continue significantly impacting the logistics and supply chain sector."
  • This quarter, Overhaul's dedication to excellence and innovation was notably recognized in the Supply & Demand Chain Executive's 2024 Pros to Know awards.
  • The G2 Spring 2024 Supply Chain Visibility Grid named Overhaul as a Leader, affirming the company's excellence in delivering state-of-the-art supply chain visibility solutions.

Supply & Demand Chain Executive Names Dan Luttner as Recipient of 2024 Pros to Know Award

Retrieved on: 
Monday, March 11, 2024
Growth, Data science, Partner (business rank), Acquisition, Pros, Publication, Partner, Machine learning, Marketing, System, Food, Demand, Retail

WASHINGTON, March 11, 2024 /PRNewswire-PRWeb/ -- Supply & Demand Chain Executive, the only publication covering the entire global supply chain, named Dan Luttner, Managing Partner at Plantensive, as one of the winners of this year's Pros to Know award, which recognizes outstanding executives whose accomplishments are an example for other leaders looking to leverage supply chain as a competitive advantage. This year's recognition is for the Lifetime Achievement category and marks the sixth consecutive year Plantensive leaders have won this distinguished award.

Key Points: 
  • The Pros to Know award recognizes supply chain leaders who are innovators and architects of efficient and responsible practices within the global supply chain industry.
  • WASHINGTON, March 11, 2024 /PRNewswire-PRWeb/ -- Supply & Demand Chain Executive, the only publication covering the entire global supply chain, named Dan Luttner, Managing Partner at Plantensive, as one of the winners of this year's Pros to Know award, which recognizes outstanding executives whose accomplishments are an example for other leaders looking to leverage supply chain as a competitive advantage.
  • As a thought leader in the supply chain space, Luttner has contributed articles to Supply & Demand Chain Executive, AWS Industry Solutions, StrategicCFO360 and other publications.
  • "As someone who's passionate about supply chain transformation, I'm honored to receive this award from Supply & Demand Chain Executive," said Luttner.

Supply & Demand Chain Executive Names Perlitch Transport Founder and CEO Jenny Perlitch as Recipient of 2024 Pros to Know Award

Retrieved on: 
Monday, March 11, 2024
Innovation, Growth, Integrity, Transportation management system, TMS, Transport, Pros, SmartWay Transport Partnership, Demand, Retail

ATLANTA, March 11, 2024 /PRNewswire/ -- MODEX 2024 -- Perlitch Transport, formerly recognized as FutureTrans, announces a significant rebranding initiative spearheaded by its visionary CEO, Jenny Perlitch. This announcement comes as Supply & Demand Chain Executive, the preeminent publication covering the global supply chain landscape, names Jenny one of this year's recipients of the Pros to Know award. This accolade celebrates executives who have demonstrated remarkable achievements, providing a blueprint for other industry leaders seeking to harness the power of the supply chain for competitive advantage.

Key Points: 
  • ATLANTA, March 11, 2024 /PRNewswire/ -- MODEX 2024 -- Perlitch Transport , formerly recognized as FutureTrans, announces a significant rebranding initiative spearheaded by its visionary CEO, Jenny Perlitch.
  • This announcement comes as Supply & Demand Chain Executive, the preeminent publication covering the global supply chain landscape, names Jenny one of this year's recipients of the Pros to Know award.
  • Recipients of this year's award are profiled in Supply & Demand Chain Executive's March 2024 issue, distributed at MODEX 2024 and at www.SDCExec.com .
  • They have spent the last year (and more) creating safer, more efficient supply chains," says Marina Mayer, editor-in-chief of Supply & Demand Chain Executive.

CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plant

Retrieved on: 
Thursday, February 29, 2024
Pros, MEG, Memorandum of understanding, Food packaging, Landbell, Clermont-Ferrand, Indorama Ventures, Ellen, PTA, CO2, Textile, MacArthur Foundation, Recycling, PET, Water, Partnership

The partnership will leverage Landbell Group’s expertise and network in the sourcing of PET packaging and textile waste which will be prepared for biorecycling.

Key Points: 
  • The partnership will leverage Landbell Group’s expertise and network in the sourcing of PET packaging and textile waste which will be prepared for biorecycling.
  • From 2026, Landbell Group will supply CARBIOS with 15 kt/year of PET flakes, ensuring a steady supply chain for sustainable PET production.
  • These flakes will serve as essential feedstock for CARBIOS’ production of food-grade PTA and MEG, further re-polymerized into PET.
  • The innovative depolymerization process developed by CARBIOS facilitates the recycling of PET waste into high-quality recycled PET.

United States and European Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Professional Services, Health, Data Analytics, Health Technology, Clinical Trials, Pharmaceutical, Pros, Clinical trial, Diary, Patient, ChromeOS, Medical imaging

The "Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024" report has been added to ResearchAndMarkets.com's offering.
  • This landmark report includes 300 patients involved in 1-2 clinical trials within the last 2 years from the United States and Europe.
  • It explores experiences with consent and onboarding (including randomization), along with preferences, areas of satisfaction, and potential future changes regarding patient diaries.
  • These diaries are critical to clinical trials as they capture data pertaining to Patient Reported Outcomes (PROs), including patient experience, symptoms, and adverse effects.

Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 1, 2024
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Cream, LTS, Pros, Therapy, Incidence, Week, Psoriasis, Dermatology, Headache, Political moderate, Atopic dermatitis, Pain, Validation, Swelling, Itch, DLQI, Skin, Irritation, Folliculitis, Accepted, Common, QD, Stinger, Safety, Abstract, Patient, Rash, San Diego Convention Center, Nose, American Academy, Vaccine

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).
  • VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation being studied in the ADORING Phase 3 development program for AD.
  • The following posters will be viewable onsite at the San Diego Convention Center.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.